High rheumatoid factor does not diminish efficacy of TNF inhibitors in seropositive JIA
Authors' conclusion
Unlike in adults, efficacy of TNFi was not diminished by elevated levels of RF in this cohort of pediatric patients with seropositive polyarthritis.
Study context
- Population
- Children with JIA/seropositive polyarthritis treated with TNF inhibitors (TNFi), admitted between November 2009 and March 2023
- Participants
- 28 children
- Exposure
- TNFi efficacy in highly elevated rheumatoid factor (RF) vs low titre RF
- RF ≥ 160 U/mln = 12
- RF < 160 U/mln = 16reference
- Outcome
- Change in JADAS27 and cJADAS27 on TNFi
Methodological detailstwo databases, repeated measures ANOVA, 21 patients (75%) etanercept, three (11%) adalimumab, four (14%) golimumab; 23 also received MTX
- Two databases
- Repeated measures ANOVA
- 21 patients (75%) etanercept, three (11%) adalimumab, four (14%) golimumab; 23 also received MTX
Main finding
As reported in the abstract
- Mean JADAS27 and cJADAS27 scores did not differ significantly between RF groups across the two time points (t-test of % improvement and ANCOVA)
Observational data: associations, not effects.
Further findings
Mean JADAS27 (cJADAS27), whole cohort
- At TNFi start, JADAS27 (cJADAS27)
- 23.0 ± 14.7 (21.0 ± 12.1)
- After starting TNFi, JADAS27 (cJADAS27)
- 4.8 ± 5.0 (4.8 ± 4.7)
Original publication
High rheumatoid factor does not diminish efficacy of TNF inhibitors in seropositive JIA. Pediatr Rheumatol Online J. Published 21 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →